GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiomX Inc (AMEX:PHGE) » Definitions » Degree of Financial Leverage

BiomX (PHGE) Degree of Financial Leverage : -0.73 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BiomX Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). BiomX's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was -0.73. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for BiomX's Degree of Financial Leverage or its related term are showing as below:

PHGE's Degree of Financial Leverage is ranked better than
89.66% of 1499 companies
in the Biotechnology industry
Industry Median: 0.97 vs PHGE: -0.73

BiomX Degree of Financial Leverage Historical Data

The historical data trend for BiomX's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiomX Degree of Financial Leverage Chart

BiomX Annual Data
Trend Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial - 0.47 0.34 1.19 4.74

BiomX Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.20 1.90 4.74 -0.73

Competitive Comparison of BiomX's Degree of Financial Leverage

For the Biotechnology subindustry, BiomX's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BiomX's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BiomX's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where BiomX's Degree of Financial Leverage falls into.



BiomX Degree of Financial Leverage Calculation

BiomX's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.61 (Mar. 2024) / -0.88 (Mar. 2023) - 1 )/( -34.424 (Mar. 2024) / -24.274 (Mar. 2023) - 1 )
=-0.3068/0.4181
=-0.73***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


BiomX  (AMEX:PHGE) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


BiomX Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of BiomX's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


BiomX (PHGE) Business Description

Industry
Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.
Executives
Assaf Oron officer: Chief Business Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Michael E. Dambach director 22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003
Jason M. Marks director C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Carl L Gordon 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Biofund Gp Limited Partnership director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Chidozie Ugwumba 10 percent owner 158 FILMORE STREET, DENVER CO 80206
Thomas Layton Walton 10 percent owner P.O. BOX 1860, BENTONVILLE AR 72712
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Lynne Marie Sullivan director C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Marina Wolfson officer: Principal Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Jonathan Eitan Solomon director, officer: Chief Executive Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Russell Greig director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004